PSI CRO Moves into a New Location in the Heart of Vienna, Austria

ZUG, Switzerland--PSI CRO, a full service Contract Research Organization, known for predictable, on-time enrollment and project delivery, has expanded its presence in Austria by moving to new offices in Vienna. The new home of PSI CRO GmbH is located in the heart of Vienna at Rennweg 9/6/1, 1030.

PSI moved to a larger office to accommodate the continued growth we are experiencing. Sonja Schneider-Schwarz, Country Manager, Director of Clinical Operations, stated "PSI is offering excellent collaboration opportunities for both clients and staff and we are excited to keep up the good work and growth in Austria. We are putting effort into careful selection and training of staff who share PSI's values and passion for on-time delivery. And we simply love our new premises. It's a gorgeous location that can be conveniently reached."

PSI is actively working in areas of Oncology, Oncohematology, Hemophilia, Infectious Diseases, Rare Diseases, Multiple Sclerosis, Nephrology, Endocrinology, Autoimmune, Gastroenterology, Cardiology and others.

About PSI CRO AG: PSI is a Swiss-based privately-owned, full-service contract research organization (CRO), operating globally. PSI's reputation on the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI's global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. Global headquarters are located in Zug (Zürich), Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com

Contacts

PSI Inquiries to:
PSI CRO AG
Barbara Breen, +1 847-202-1120
[email protected]

 

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.